Corrigendum: CDKN2A determines mesothelioma cell fate to EZH2 inhibition

Giulia Pinton*, Zhuo Wang, Cecilia Balzano, Sara Missaglia, Daniela Tavian, Renzo Boldorini, Dean A. Fennell, Martin Griffin, Laura Moro*

*Corresponding author for this work

Research output: Contribution to journalCorrectionpeer-review

Original languageEnglish
Article number1081632
Number of pages1
JournalFrontiers in Oncology
Early online date23 Nov 2022
Publication statusPublished - 23 Nov 2022

Bibliographical note

Copyright © 2022 Pinton, Wang, Balzano, Missaglia, Tavian, Boldorini, Fennell, Griffin and Moro. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Funding Information:
In the original article, there was an error in the Funding statement as published. The correct funding statement is “The authors acknowledge the financial support of project HERMES (HEreditary Risk in MESothelioma) and Università del Piemonte Orientale (Bando ricerca locale 2019)”.


  • Oncology
  • malignant pleural mesothelioma
  • EZH2 inhibitor
  • CDKN2A/p16ink4a
  • TG2
  • multicellular spheroids

Cite this